Looking to expand your partner network with leading companies like Allergy Therapeutics? Consider joining Inpart's global network for free.
News and Trends 8 Dec 2022
Allergy Therapeutics moves ahead with peanut and grass pollen allergy trials
Allergy Therapeutics has announced the first subject has been dosed in the pivotal phase III G306 trial, to evaluate the efficacy and safety of Grass MATA MPL. Grass MATA MPL is Allergy Therapeutics’ short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate, which aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen. Grass […]